British multinational GlaxoSmithKline (GSK) have acquired US oncology firm Tesaro for $5.1 billion (£4 billion).
Tesaro, a Massachusetts-based clinical stage biopharmaceutical company, won approval for ovarian cancer drug Zejula in March 2017. Zejula, an oral poly ADP ribose polymerase (PARP) inhibitor, is currently approved in the US and Europe for adults with recurrent ovarian cancer.
![[column] Toekomst tijdschriften glanst als nooit tevoren](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/happy-couple-in-t-shirts-reading-newspaper-while-h-2024-11-10-00-13-23-utc-1-80x60.jpg)
![[column] MarketingAffairs 17: Marketing als oplossing](https://www.pharmamarketeer.nl/wp-content/uploads/2024/12/asian-seo-manager-writing-on-glass-with-illustrati-2024-11-17-23-11-51-utc-1-80x60.jpg)
